Rebamipide
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Keratoconjunctivitis Sicca
Conditions
Keratoconjunctivitis Sicca
Trial Timeline
May 1, 2004 → Jul 1, 2006
NCT ID
NCT00201955About Rebamipide
Rebamipide is a phase 3 stage product being developed by Novartis for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT00201955. Target conditions include Keratoconjunctivitis Sicca.
What happened to similar drugs?
1 of 8 similar drugs in Keratoconjunctivitis Sicca were approved
Approved (1) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00201981 | Phase 3 | Completed |
| NCT00201955 | Phase 3 | Completed |
Competing Products
15 competing products in Keratoconjunctivitis Sicca
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FK506 | Astellas Pharma | Phase 3 | 40 |
| FK506 + placebo | Astellas Pharma | Phase 3 | 40 |
| OTX-101 0.09% | Sun Pharmaceutical | Phase 3 | 40 |
| OTX-101 0.05% + OTX-101 0.09% + Vehicle | Sun Pharmaceutical | Phase 2/3 | 38 |
| cyclosporine + vehicle of OTX-101 | Sun Pharmaceutical | Phase 3 | 40 |
| INS365 Ophthalmic Solution | Merck | Phase 3 | 40 |
| Pimecrolimus + Vehicle | Novartis | Phase 2 | 35 |
| Cyclosporine A + Dexamethasone | Novartis | Approved | 43 |
| Rebamipide | Novartis | Phase 3 | 40 |
| Tasocitinib + Tasocitinib + vehicle for Tasocitinib | Pfizer | Phase 2 | 27 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 31 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo | Rigel Pharmaceuticals | Phase 1 | 23 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo | Rigel Pharmaceuticals | Phase 2 | 29 |
| CF101 | Can Fite Biopharma | Phase 3 | 30 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 25 |